Skip to main content
SpringerLink
Log in

Encapsulating Peritoneal Sclerosis

  • Reference work entry
  • First Online:
Nolph and Gokal's Textbook of Peritoneal Dialysis

  • 431 Accesses

Abstract

Encapsulating peritoneal sclerosis (EPS) is the most serious complication of long-term PD. In this chapter a review will be given on risk factors, EPS epidemiology, its pathology, pathogenesis, clinical manifestations, investigations, treatment, and prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Johnson DW, Cho Y, Livingston BE, Hawley CM, McDonald SP, Brown FG, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int. 2010;77(10):904–12.

    Article  PubMed  Google Scholar 

  2. Korte MR, Sampimon DE, Betjes MG, Krediet RT. Encapsulating peritoneal sclerosis: the state of affairs. Nat Rev Nephrol. 2011;7(9):528–38.

    Article  CAS  PubMed  Google Scholar 

  3. Braun N, Fritz P, Ulmer C, Latus J, Kimmel M, Biegger D, et al. Histological criteria for encapsulating peritoneal sclerosis – a standardized approach. PLoS One. 2012;7(11):e48647.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ryckelynck JP, Bechade C, Bouvier N, Ficheux M, Hurault de LB, Lobbedez T. Encapsulating peritoneal sclerosis. Nephrol Ther. 2017;13(4):211–9.

    Article  PubMed  Google Scholar 

  5. Singhal M, Krishna S, Lal A, Narayanasamy S, Bal A, Yadav TD, et al. Encapsulating peritoneal sclerosis: the abdominal cocoon. Radiographics. 2019;39(1):62–77.

    Article  PubMed  Google Scholar 

  6. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004;44(4):729–37.

    Article  PubMed  Google Scholar 

  7. Brown MC, Simpson K, Kerssens JJ, Mactier RA. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol. 2009;4(7):1222–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Brown EA, Bargman J, Van BW, Chang MY, Finkelstein FO, Hurst H, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis – position paper for ISPD: 2017 update. Perit Dial Int. 2017;37(4):362–74.

    Article  PubMed  Google Scholar 

  9. Korte MR, Sampimon DE, Lingsma HF, Fieren MW, Looman CW, Zietse R, et al. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int. 2011;31(3):269–78.

    Article  PubMed  Google Scholar 

  10. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20(Suppl 4):S43–55.

    Article  PubMed  Google Scholar 

  11. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant. 1988;3(1):66–9.

    CAS  PubMed  Google Scholar 

  12. Hendriks PM, Ho-dac-Pannekeet MM, van Gulik TM, Struijk DG, Phoa SS, Sie L, et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit Dial Int. 1997;17(2):136–43.

    Article  CAS  PubMed  Google Scholar 

  13. van Westrhenen R, Aten J, Hajji N, de Boer OJ, Kunne C, de Waart DR, et al. Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif. 2007;25(5–6):466–72.

    Article  PubMed  Google Scholar 

  14. Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int. 2007;27(6):619–24.

    Article  PubMed  Google Scholar 

  15. Korte MR, Habib SM, Lingsma H, Weimar W, Betjes MG. Posttransplantation encapsulating peritoneal sclerosis contributes significantly to mortality after kidney transplantation. Am J Transplant. 2011;11(3):599–605.

    Article  CAS  PubMed  Google Scholar 

  16. Slingeneyer A, Mion C, Mourad G, Canaud B, Faller B, Beraud JJ. Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs. 1983;29:633–40.

    CAS  PubMed  Google Scholar 

  17. Verger C, Celicout B. Peritoneal permeability and encapsulating peritonitis. Lancet. 1985;1(8435):986–7.

    Article  CAS  PubMed  Google Scholar 

  18. Summers AM, Abrahams AC, Alscher MD, Betjes M, Boeschoten EW, Braun N, et al. A collaborative approach to understanding EPS: the European perspective. Perit Dial Int. 2011;31(3):245–8.

    Article  PubMed  Google Scholar 

  19. Balasubramaniam G, Brown EA, Davenport A, Cairns H, Cooper B, Fan SL, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24(10):3209–15.

    Article  PubMed  Google Scholar 

  20. Nakayama M, Miyazaki M, Honda K, Kasai K, Tomo T, Nakamoto H, et al. Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study. Perit Dial Int. 2014;34(7):766–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Betjes MG, Habib SM, Boeschoten EW, Hemke AC, Struijk DG, Westerhuis R, et al. Significant decreasing incidence of encapsulating peritoneal sclerosis in the Dutch population of peritoneal dialysis patients. Perit Dial Int. 2017;37(2):230–4.

    Article  PubMed  Google Scholar 

  22. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers MM, Mulder J, Struijk DG, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int. 1999;19(6):517–25.

    Article  CAS  PubMed  Google Scholar 

  23. Williams JD, Craig KJ, Topley N, Von RC, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470–9.

    Article  PubMed  Google Scholar 

  24. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol. 2008;3(3):720–8.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol. 2010;21(7):1077–85.

    Article  CAS  PubMed  Google Scholar 

  26. Latus J, Habib SM, Kitterer D, Korte MR, Ulmer C, Fritz P, et al. Histological and clinical findings in patients with post-transplantation and classical encapsulating peritoneal sclerosis: a European multicenter study. PLoS One. 2014;9(8):e106511.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Habib SM, Abrahams AC, Korte MR, Zietse R, de Vogel LL, Boer WH, et al. CD4-positive T cells and M2 macrophages dominate the peritoneal infiltrate of patients with encapsulating peritoneal sclerosis. PLoS One. 2015;10(4):e0120174.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Morelle J, Sow A, Hautem N, Bouzin C, Crott R, Devuyst O, et al. Interstitial fibrosis restricts osmotic water transport in encapsulating peritoneal sclerosis. J Am Soc Nephrol. 2015;26(10):2521–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Combet S, Ferrier ML, Van LM, Stoenoiu M, Moulin P, Miyata T, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol. 2001;12(10):2146–57.

    Article  CAS  PubMed  Google Scholar 

  30. Fullerton GD, Amurao MR. Evidence that collagen and tendon have monolayer water coverage in the native state. Cell Biol Int. 2006;30(1):56–65.

    Article  CAS  PubMed  Google Scholar 

  31. Michels WM, Verduijn M, Parikova A, Boeschoten EW, Struijk DG, Dekker FW, et al. Time course of peritoneal function in automated and continuous peritoneal dialysis. Perit Dial Int. 2012;32(6):605–11.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25(Suppl 4):S39–47.

    Article  PubMed  Google Scholar 

  33. Garosi G. Different aspects of peritoneal damage: fibrosis and sclerosis. Contrib Nephrol. 2009;163:45–53.

    Article  PubMed  Google Scholar 

  34. Betjes MG, Habib MS, Struijk DG, Lopes BD, Korte MR, Abrahams AC, et al. Encapsulating peritoneal sclerosis is associated with T-cell activation. Nephrol Dial Transplant. 2015;30(9):1568–76.

    Article  CAS  PubMed  Google Scholar 

  35. Abrahams AC, Habib SM, Dendooven A, Riser BL, van der Veer JW, Toorop RJ, et al. Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-beta1, and vascular endothelial growth factor. PLoS One. 2014;9(11):e112050.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med. 2003;348(5):403–13.

    Article  PubMed  Google Scholar 

  37. Del Peso G, Jimenez-Heffernan JA, Bajo MA, Aroeira LS, Aguilera A, Fernandez-Perpen A, et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl. 2008;108:S26–33.

    Article  Google Scholar 

  38. Aroeira LS, Aguilera A, Selgas R, Ramirez-Huesca M, Perez-Lozano ML, Cirugeda A, et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis. 2005;46(5):938–48.

    Article  CAS  PubMed  Google Scholar 

  39. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325(12):836–42.

    Article  CAS  PubMed  Google Scholar 

  40. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int. 1999;19(4):325–33.

    Article  CAS  PubMed  Google Scholar 

  41. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol. 2000;11(4):717–28.

    Article  CAS  PubMed  Google Scholar 

  42. Kawanishi K, Honda K, Tsukada M, Oda H, Nitta K. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Perit Dial Int. 2013;33(3):242–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Hamada C, Honda K, Kawanishi K, Nakamoto H, Ito Y, Sakurada T, et al. Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution. J Artif Organs. 2015;18(3):243–50.

    Article  CAS  PubMed  Google Scholar 

  44. Del Peso G, Jimenez-Heffernan JA, Selgas R, Remon C, Ossorio M, Fernandez-Perpen A, et al. Biocompatible dialysis solutions preserve peritoneal mesothelial cell and Vessel Wall integrity. A case-control study on human biopsies. Perit Dial Int. 2016;36(2):129–34.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Vlijm A, Van SJ, Lamers AB, Struijk DG, Krediet RT. Imaging in encapsulating peritoneal sclerosis. NDT Plus. 2011;4(5):281–4.

    PubMed  PubMed Central  Google Scholar 

  46. Stafford-Johnson DB, Wilson TE, Francis IR, Swartz R. CT appearance of sclerosing peritonitis in patients on chronic ambulatory peritoneal dialysis. J Comput Assist Tomogr. 1998;22(2):295–9.

    Article  CAS  PubMed  Google Scholar 

  47. Tarzi RM, Lim A, Moser S, Ahmad S, George A, Balasubramaniam G, et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol. 2008;3(6):1702–10.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Vlijm A, Stoker J, Bipat S, Spijkerboer AM, Phoa SS, Maes R, et al. Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int. 2009;29(5):517–22.

    Article  PubMed  Google Scholar 

  49. Habib SM, Korte MR, Betjes MG. Lower mortality and inflammation from post-transplantation encapsulating peritoneal sclerosis compared to the classical form. Am J Nephrol. 2013;37(3):223–30.

    Article  PubMed  Google Scholar 

  50. Lopes BD, Krediet RT. Current status and practical use of effluent biomarkers in peritoneal dialysis patients. Am J Kidney Dis. 2013;62(4):823–33.

    Article  Google Scholar 

  51. Zemel D, Koomen GC, Hart AA, ten Berge IJ, Struijk DG, Krediet RT. Relationship of TNF-alpha, interleukin-6, and prostaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med. 1993;122(6):686–96.

    CAS  PubMed  Google Scholar 

  52. Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel P, Abensur H, Romao JE Jr, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant. 2002;17(8):1480–6.

    Article  CAS  PubMed  Google Scholar 

  53. Lambie M, Chess J, Donovan KL, Kim YL, Do JY, Lee HB, et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol. 2013;24(12):2071–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Krediet RT. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int. 2001;21(6):560–7.

    Article  CAS  PubMed  Google Scholar 

  55. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int. 1997;51(3):888–93.

    Article  CAS  PubMed  Google Scholar 

  56. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med. 1999;134(2):124–32.

    Article  CAS  PubMed  Google Scholar 

  57. Le Poole CY, Welten AG, Ter Wee PM, Paauw NJ, Djorai AN, Valentijn RM, et al. A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation. Perit Dial Int. 2012;32(3):305–15.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 1992;95(2–3):105–17.

    Article  CAS  PubMed  Google Scholar 

  59. Holmdahl L, Falkenberg M, Ivarsson ML, Risberg B. Plasminogen activators and inhibitors in peritoneal tissue. APMIS. 1997;105(1):25–30.

    Article  CAS  PubMed  Google Scholar 

  60. Lopes Barreto L, Coester AM, Struijk DG, Krediet RT. Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients? Perit Dial Int. 2013;33(5):529–37.

    Article  Google Scholar 

  61. Sampimon DE, Korte MR, Barreto DL, Vlijm A, de Waart R, Struijk DG, et al. Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int. 2010;30(2):163–9.

    Article  CAS  PubMed  Google Scholar 

  62. Lopes Barreto D, Struijk DG, Krediet RT. Peritoneal effluent MMP-2 and PAI-1 in encapsulating peritoneal sclerosis. Am J Kidney Dis. 2015;65(5):748–53.

    Article  CAS  PubMed  Google Scholar 

  63. Lopes Barreto D, Sampimon DE, Struijk DG, Krediet RT. Early detection of imminent encapsulating peritoneal sclerosis: free water transport, selected effluent proteins, or both? Perit Dial Int. 2019;39(1):83–9.

    Article  Google Scholar 

  64. Krediet RT, Struijk DG, Boeschoten EW, Koomen GC, Stouthard JM, Hoek FJ, et al. The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis patients who develop sclerosing peritonitis. Am J Kidney Dis. 1989;13(4):299–307.

    Article  CAS  PubMed  Google Scholar 

  65. Sampimon DE, Coester AM, Struijk DG, Krediet RT. Time course of peritoneal transport parameters in peritoneal dialysis patients who develop peritoneal sclerosis. Adv Perit Dial. 2007;23:107–11.

    PubMed  Google Scholar 

  66. Sampimon DE, Coester AM, Struijk DG, Krediet RT. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2011;26(1):291–8.

    Article  PubMed  Google Scholar 

  67. Yamamoto R, Nakayama M, Hasegawa T, Miwako N, Yamamoto H, Yokoyami K, et al. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial. 2002;18:131–4.

    CAS  PubMed  Google Scholar 

  68. Mujais S, Nolph K, Gokal R, Blake P, Burkart J, Coles G, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2000;20(Suppl 4):S5–21.

    Article  PubMed  Google Scholar 

  69. Rippe B, Stelin G. Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism. Kidney Int. 1989;35(5):1234–44.

    Article  CAS  PubMed  Google Scholar 

  70. Rippe B, Carlsson O. Role of transcellular water channels in peritoneal dialysis. Perit Dial Int. 1999;19(Suppl 2):S95–101.

    Article  PubMed  Google Scholar 

  71. Nolph KD, Hano JE, Teschan PE. Peritoneal sodium transport during hypertonic peritoneal dialysis. Physiologic mechanisms and clinical implications. Ann Intern Med. 1969;70(5):931–41.

    Article  CAS  PubMed  Google Scholar 

  72. Smit W, Struijk DG, Ho-Dac-Pannekeet MM, Krediet RT. Quantification of free water transport in peritoneal dialysis. Kidney Int. 2004;66(2):849–54.

    Article  PubMed  Google Scholar 

  73. Waniewski J, Debowska M, Lindholm B. Water and solute transport through different types of pores in peritoneal membrane in CAPD patients with ultrafiltration failure. Perit Dial Int. 2009;29(6):664–9.

    Article  PubMed  Google Scholar 

  74. Coester AM, Smit W, Struijk DG, Parikova A, Krediet RT. Longitudinal analysis of peritoneal fluid transport and its determinants in a cohort of incident peritoneal dialysis patients. Perit Dial Int. 2014;34(2):195–203.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int. 2004;66(6):2437–45.

    Article  CAS  PubMed  Google Scholar 

  76. Lambie ML, John B, Mushahar L, Huckvale C, Davies SJ. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int. 2010;78(6):611–8.

    PubMed  Google Scholar 

  77. Morelle J, Sow A, Hautem N, Devuyst O, Goffin E. Ultrafiltration failure and impaired sodium sieving during long-term peritoneal dialysis: more than aquaporin dysfunction? Perit Dial Int. 2016;36(2):227–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Vlahu CA, Krediet RT. Can plasma Hyaluronan and hyaluronidase be used as markers of the endothelial Glycocalyx state in patients with kidney disease? Adv Perit Dial. 2015;31:3–6.

    CAS  PubMed  Google Scholar 

  79. Moriishi M, Kawanishi H, Kawai T, Takahashi S, Hirai T, Shishida M, et al. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial. 2002;18:149–53.

    PubMed  Google Scholar 

  80. Yamamoto T, Nagasue K, Okuno S, Yamakawa T. The role of peritoneal lavage and the prognostic significance of mesothelial cell area in preventing encapsulating peritoneal sclerosis. Perit Dial Int. 2010;30(3):343–52.

    Article  PubMed  Google Scholar 

  81. Kasuga H. After peritoneal dialysis discontinuation: when will we remove peritoneal dialysis catheter? J Vasc Access. 2019;20(Suppl 1):31–4.

    Article  PubMed  Google Scholar 

  82. De Freitas D, Jordaan A, Williams R, Alderdice J, Curwell J, Hurst H, et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28(3):271–6.

    Article  PubMed  Google Scholar 

  83. El-Sherbini N, Duncan N, Hickson M, Johansson L, Brown EA. Nutrition changes in conservatively treated patients with encapsulating peritoneal sclerosis. Perit Dial Int. 2013;33(5):538–43.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Dejagere T, Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. Am J Kidney Dis. 2005;45(2):e33–7.

    Article  PubMed  Google Scholar 

  85. Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley PE, Augustine T, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int. 2005;68(5):2381–8.

    Article  PubMed  Google Scholar 

  86. Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int. 2006;26(2):203–6.

    Article  CAS  PubMed  Google Scholar 

  87. Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MG. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch multicentre EPS study. Nephrol Dial Transplant. 2011;26(2):691–7.

    Article  CAS  PubMed  Google Scholar 

  88. Kawanishi H, Moriishi M, Ide K, Dohi K. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28(Suppl 3):S205–10.

    Article  PubMed  Google Scholar 

  89. Kawanishi H, Shintaku S, Moriishi M, Dohi K, Tsuchiya S. Seventeen years’ experience of surgical options for encapsulating peritoneal sclerosis. Adv Perit Dial. 2011;27:53–8.

    PubMed  Google Scholar 

  90. Kawanishi H, Banshodani M, Yamashita M, Shintaku S, Dohi K. Surgical treatment for encapsulating peritoneal sclerosis: 24 Years’ experience. Perit Dial Int. 2019;39(2):169–74.

    Article  PubMed  Google Scholar 

  91. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract. 2009;111(2):c149–54.

    Article  CAS  PubMed  Google Scholar 

  92. Campbell R, Augustine T, Hurst H, Pararajasingam R, Van DD, Armstrong S, et al. Anthropometrics identify wasting in patients undergoing surgery for encapsulating peritoneal sclerosis. Perit Dial Int. 2015;35(4):471–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Latus J, Ulmer C, Fritz P, Rettenmaier B, Biegger D, Lang T, et al. Encapsulating peritoneal sclerosis: a rare, serious but potentially curable complication of peritoneal dialysis-experience of a referral centre in Germany. Nephrol Dial Transplant. 2013;28(4):1021–30.

    Article  PubMed  Google Scholar 

  94. Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int. 2007;27(6):619–24. DOUBLON

    Article  PubMed  Google Scholar 

  95. Garosi G, Oreopoulos DG. No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis. Int Urol Nephrol. 2009;41(4):903–7.

    Article  PubMed  Google Scholar 

  96. Kawaguchi Y. No need for an “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis: comments from around the world. Int Urol Nephrol. 2010;42(1):239.

    Article  PubMed  Google Scholar 

  97. Lambie M, Teece L, Johnson DW, Petrie M, Mactier R, Solis-Trapala I, et al. Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death. Nephrol Dial Transplant. 2019;34(9):1585–1591.

    Google Scholar 

  98. Cnossen TT, Smit W, Konings CJ, Kooman JP, Leunissen KM, Krediet RT. Quantification of free water transport during the peritoneal equilibration test. Perit Dial Int. 2009;29(5):523–7.

    Article  PubMed  Google Scholar 

  99. Schaefer B, Bartosova M, Macher-Goeppinger S, Sallay P, Voros P, Ranchin B, et al. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis. Kidney Int. 2018;94(2):419–29.

    Article  CAS  PubMed  Google Scholar 

  100. Elphick EH, Teece L, Chess JA, Do JY, Kim YL, Lee HB, et al. Biocompatible solutions and long-term changes in peritoneal solute transport. Clin J Am Soc Nephrol. 2018;13(10):1526–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Van Diepen ATN, Coester AM, Janmaat CJ, Dekker FW, Struijk DG, Krediet RT. Comparison of longitudinal membrane function in peritoneal dialysis patients according to dialysis fluid biocompatibility. Kidney Int Rep. 2020;5:2183–3194.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology, Cliniques Universitaires Saint-Luc, Brussels, Belgium

    E. J. Goffin

  2. Division of Nephrology, Academic Medical Center – University of Amsterdam, Amsterdam, The Netherlands

    Raymond T. Krediet

Authors
  1. E. J. Goffin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond T. Krediet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. J. Goffin .

Editor information

Editors and Affiliations

  1. University of Missouri, Columbia, MO, USA

    Ramesh Khanna

  2. Dept. Medicine Div. Nephrology, University of Amsterdam Academic Medical Center, Amsterdam, The Netherlands

    Raymond T. Krediet

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Goffin, E.J., Krediet, R.T. (2023). Encapsulating Peritoneal Sclerosis. In: Khanna, R., Krediet, R.T. (eds) Nolph and Gokal's Textbook of Peritoneal Dialysis. Springer, Cham. https://doi.org/10.1007/978-3-030-62087-5_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62087-5_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62086-8

  • Online ISBN: 978-3-030-62087-5

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation